A statement from the Bionical Emas Group on guidance & measures regarding COVID-19 - read here

In relation to staff and visitor safety, we have full risk assessments in place for all of our workplaces. These risk assessments are revisited and updated regularly, to reflect changing risks, knowledge and circumstances, and to reflect evolving Government guidance. We have not placed the risk assessments here on the website as they would become out of date too quickly. However, you are welcome to email info@bionical-emas.com to request access to our most up to date risk assessments applicable to your needs. Please note that all our staff are notified of all applicable risk assessments and updates, along with ‘quick guides’ automatically via our e-learning system.

HomeNews & ResourcesOxford Hub Launch
featured image

London, United Kingdom – Bionical Ltd. T/A Bionical Emas, the first and only full-service Clinical research Organization combining Clinical Development, Early Access Programs and Clinical Trial Supply, is proud to announce the opening of a new office in Oxford, England.

The Oxford office is to be led and managed by Peter Embley, SVP Pharmacovigilance, Regulatory & Health Economic Science. Peter stated, “The Hub expresses our intent to be amongst our clients and stakeholders, in one of Europe’s key science technology and business environments, to better understand their requirements and provide a customized, solution-based service’. He added ‘The launch coincides with our new service, Bionical Emas Consults. BEC is a range of flexible consultancy services, from strategic regulatory advice to pharmacovigilance, pricing & reimbursement roadmaps, to strategic partnership solutions.”

Danny Nasmyth-Miller, Executive Vice President Clinical Development at Bionical Emas, shared his thoughts about the latest addition to the growing Bionical Emas group: “We are proud to provide our customers with office-based staff across the UK and Europe. The Oxford office enables us to enact upon our desire to directly contribute to the development of innovative new medicines, technologies and devices at source. As we continue to rapidly expand, we look to build our global presence in strategic locations, to support our desire to be recognized as the leading global specialist CRO.”

For more information about Bionical Emas, please contact info@bionical-emas.com.

Bionical Emas.

Bionical Emas is the only CRO to combine Clinical Development, Early Access Programs and Clinical Trial Supply, to deliver a unique, seamless approach bringing new medicines to patients faster. Through our dedication and commitment to our customers we can provide unique, integrated services, shaped to fit any clinical need, ultimately accelerating the drug development process and providing earlier access to medicine for patients.

Bionical Emas bring decades of experience developing and commercializing medicines at global, regional, and national levels. We provide full service, end-to-end support to drive pharmaceutical and biotech product development from first-in-human to the end of the product lifecycle.

We can support you with…

BE Consults

The Bionical Emas team is your ideal strategic, regulatory, consultancy partner. Providing a range of services, from ad-hoc, specific regulatory, technical or therapeutic advice, to comprehensive, full-service provisions. We provide a range of drug development solutions for our clients, including; Regulatory Services, Quality Assurance, Data Management, Pharmacovigilance, Clinical Operations and Early Access Programs.


How can we support you?

Our dedicated teams of experts are on hand to help should you require any additional resource or further information about our services.